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Melanoma therapyThe tumour suppressor p53 is a master sensor of stress and it controls the expression of hundreds to
thousands of genes with diverse biological functions including cell cycle arrest, apoptosis, and
senescence. Consequently p53 is the most mutated gene found in human cancer and p53 mutation
rate varies from 5% to 95%. Importantly p53 activity is often inactivated in tumours expressing
structurally wild type p53. Thus one of the major challenges in cancer research is to restore the
tumour suppressive function of p53. Intensive studies in the past decade have demonstrated that
in addition to mutation, p53 activities are largely regulated by cellular factors that control the
expression level and/or transcriptional activities of p53. MDM2, MDM4, p14ARF and the ASPP family
of proteins are among themost studied regulators of p53. With increased understanding of the com-
plexity of p53 regulation, various p53 reactivating approaches are being developed. This review will
focus on the recent understanding of p53 inactivation in melanoma and the approaches to
reactivate p53 in preclinical studies. Recent success in the therapeutic targeting of the BRAFV600E
oncogenic protein was accompanied with subsequent relapse caused by acquired drug resistance.
Restoration of the tumour suppressive function of p53 presents a parallel cancer therapeutic
opportunity alongside BRAFV600E inhibition. Thus targeted therapy and concurrent reactivation
of p53 may be a fertile ground to achieve synergistic killing of the 50% of cancer cells that express
structurally wild type p53.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction: The tumour suppressor p53
Discovered thirty-ﬁve years ago, the tumour suppressor TP53 is
the most mutated gene found in human cancer with the p53 gene
being mutated in around 50% of human cancer cases. As a tran-
scription factor, p53 is able to transactivate and transrepress
numerous target genes. Hundreds of p53 target genes have been
identiﬁed and characterized to date, and they are involved in
diverse biological processes including cell cycle arrest, apoptosis,
DNA repair, differentiation, angiogenesis and metabolism. Over
80% of p53 mutations occur in p53’s DNA-binding domain (DBD)
and many of the cancer derived p53 mutations inactivate its tran-
scriptional function [1]. The importance of the transcriptional
activity of p53 in mediating its tumour suppressive function has
been demonstrated experimentally through mutant p53 mouse
models. The transgenic mouse carrying a transactivation-dead
p53 with quadruple missense mutations at residues 25, 26, 53
and 54 in the transactivation domains of p53, p5325,26,53,54, istumour prone, analogous to loss of p53 [2]. Interestingly, the
mouse expressing the transcriptionally impaired mutant p5325,26,
is not susceptible to develop spontaneous tumours even though
p5325,26 is defective in inducing G1-arrest or apoptosis. However,
p5325,26 is capable of inducing senescence. Consistent with this, a
p53 knock-in mouse possessing triple mutations of p53 at three
lysine residues (121, 164 and 165), p533KR/3KR, is also not tumour
prone even though p533KR/3KR is largely defective in inducing p53
target genes involved in cell cycle arrest and apoptosis [3]. More-
over p53 in a transgenic mouse deleted for three of its most stud-
ied target genes, p21waf1, PUMA and Noxa that are involved in cell
cycle arrest and apoptosis, also maintains its tumour suppressive
function [4]. All these recent studies illustrated that despite exten-
sive studies of p53 target genes we know very little about the key
p53 targets that mediate its tumour suppressive function. These
ﬁndings reinforced the urgent need to understand the complex
barcode of p53 function [5].
Nonetheless, the transcriptional activity of p53 is crucial for its
tumour suppressive function. Importantly, the majority of p53
mutations detected in human cancers occur in the central DBD of
p53, a region that is evolutionarily conserved and shares signiﬁcant
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in p53 can enhance its ability to bind p63 and p73 [6–8]. In addi-
tion to DNA, increasing numbers of proteins have been identiﬁed
to bind the DBDs of p53. The DNA tumour viral protein SV40 Large
T antigen binds the DBD of p53 and inactivates its tumour suppres-
sive function suggesting that mutations in the DBD of p53 may
alter its ability to interact with proteins as well as DNA [9,10].
Consistent with this, a co-crystal structure of the DBD of p53 and
the C-terminus of ASPP2, the ﬁrst identiﬁed DBD interacting cellu-
lar protein of p53, illustrated that a number of p53 residues that
only contact ASPP2 but not DNA are among the top 20 most
mutated residues of p53 found in human cancers. Furthermore,
the most frequently mutated p53 hotspots, p53R248Q and
p53R273H, contact both DNA and ASPP2 [11,12]. A co-crystal struc-
ture between the DNA binding domain of p73 and the C-terminus
of ASPP2 has also been recently solved [13]. ASPP2/p53 and ASPP2/
p73 interactions are able to enhance the transcriptional activities
of p53 or p73 on selected target genes [14,15]. It is therefore
tempting to speculate that in addition to binding DNA, the ability
of p53 to interact with its siblings and cellular interacting proteins
may also contribute to its tumour suppressive function.
p53 is mutated in around half of human cancers. However, the
mutation frequency of p53 among different cancer types varies
dramatically ranging from less than 10% in prostate and leukaemia,
to around 50–70% in human lung and colon cancer and up to 95% in
human ovarian cancer (http://p53.iarc.fr/, http://cancerge-
nome.nih.gov/). Those cancer types with high p53 mutation fre-
quencies, such as lung, colon and ovarian, tend to have a high
background mutation load [1]. One exception to this rule is human
melanoma. Although its background mutation load is similar as
that seen in lung and colon cancers, p53 is only mutated in 10–
20% of humanmelanoma [16], in contrast to the high p53 mutation
frequency (50–70%) observed in human lung and colon cancer. A
key question is why p53 is rarely mutated in human melanomas.
Answers to this question will enable us to identify ways to inhibit
tumour growth by restoring the tumour suppressive function of
p53 in tumours that express structurally wild type p53.
Metastatic melanoma is characteristically refractory to treat-
ment and accounts for 80% of skin cancer deaths [17]. Around
20% and 50% of melanomas have activating mutations of N-RAS
and BRAF respectively, with elevated RAS/RAF kinase activities
promoting tumour growth [18]. Recent advances in BRAF inhibi-
tors, such as vemurafenib, have underscored the importance of
the BRAF oncogene in the development and maintenance of mela-
noma. Vemurafenib inhibits cell proliferation by selectively target-
ing BRAFV600E expressing melanoma [19]. Despite promising
results in inhibiting melanoma growth in the initial stages of treat-
ment, the majority of vemurafenib treated patients relapse within
a few months. Mechanisms of acquired drug resistance have been
attributed to an up-regulation of PDGFR or N-Ras mutation [20,21].
To overcome acquired drug resistance, co-targeting BRAFV600E
and MEK has been suggested [22]. However, as BRAF and MEK
are components of the same signalling pathway, it is difﬁcult toFig. 1. Genetic alteration of TP53, MDM2, MDM4 and CDKN2A in melanoma. Bar graph s
CDKN2A across the set of melanoma patients recorded in TCGA.predict whether targeting two nodes of the same pathway will
achieve a sustained clinical response. An alternative strategy
would be to target two independent pathways, with p53 as an
attractive option since it functions largely independent of BRAF.
BRAFV600E is present in around 50% of human melanoma; how-
ever, up to 84% of human melanoma express wild type p53
(Fig. 1, cBioPortal, TCGA skin cutaneous melanoma data) [23,24],
indicating the opportunity to reactivate p53 in melanoma.
2. p53 inactivation in human melanoma
MDM2 and MDM4 are the most well-known p53 inhibitors.
They both bind the N-terminal transcriptional domain of p53 and
inhibit p53 transcriptional activity [25,26] An additional function
of MDM2 is to bind p53 and act as the E3 ubiquitin ligase to target
p53 for proteasome mediated protein degradation [27]. MDM4 is
highly homologous to MDM2 although lacks ubiquitin ligase activ-
ity. MDM4 inhibits p53 activity mainly through its ability to bind
MDM2 [28]. The oncogenic properties of MDM2 and MDM4 are
experimentally demonstrated using MDM2 and MDM4 transgenic
mice. In human tumours, both MDM2 and MDM4 are frequently
overexpressed due to gene ampliﬁcation [29–32]. Additionally,
inactivation of p53 in melanoma may also be achieved through a
frequent deletion in CDKN2A[33], which inactivates both p14ARF
and p16INK4A. p14ARF bindsMDM2 and preventsMDM2 from target-
ing p53 for degradation [34]. p14ARF also functions as a p53 activa-
tor by potentiating MDM2-MDM4 binding and thus promoting
MDM4 degradation [35]. Consistent with this, mutation analysis
of existing skin cutaneous melanoma sequencing data showed that
p53 mutation or deletion (17%), MDM2 ampliﬁcation (4%) and
CDKN2A deletion or mutation (42%) occur in around 55% of
melanoma cases. Importantly, MDM2 ampliﬁcation and CDKN2A
deletion mainly occur in wild type p53 expressing melanoma
(Fig. 1). Ampliﬁcation and mutation of MDM4 occurs in 6% of mel-
anoma cases. Interestingly MDM2 and MDM4 ampliﬁcation are
almost mutually exclusive and they predominantly occur in wild
type p53 expressing cells. Most CDKN2A deletions occur in wild
type p53 expressing melanomas that do not have MDM2 and
MDM4 ampliﬁcations (Fig. 1). All these ﬁndings suggest that
MDM2 and MDM4 overexpression or loss of p14ARF may contribute
to the inactivation of wild type p53 function. The importance of p53
in suppressing melanoma growth is supported by the rapid
proliferation of BRAFV600E containing melanocytes on loss of p53
function [36]. Also, p53 prevents progression of naevi to
melanoma in a transgenic mouse model [37]. In agreement with
this Avery-Kiejda et al. observed abnormal expression of p53
downstream target genes, in particular pro-apoptotic genes
including Bax and PIG3 in melanoma [38]. It has now been
established that despite containing structurally wild type p53, the
tumour suppressive function of p53 in melanoma cells is largely
lost. Since TP53, MDM2, MDM4, and CDKN2A alterations only occur
in around 50% of wild type p53 expressing human melanoma
(Fig. 1), one of the major questions in melanoma and p53 researchhows the mutation and copy number alteration proﬁle of TP53, MDM2, MDM4 and
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p14ARF. Answers to these questions are crucial to restore the
tumour suppressive function of p53.
3. Reactivating p53 by inhibiting MDM2 and MDM4 in human
melanoma
Pharmacological targeting of MDM2 to prevent binding and
subsequent p53 degradation with small molecules is a conceptu-
ally viable strategy to reactivate p53. The most well-studied small
molecule inhibitor is Nutlin3, which speciﬁcally disrupts the inter-
action between MDM2 and p53 [39]. As a result, Nutlin3 can stabi-
lize p53 in MDM2 overexpressing cells and consequently up
regulates the expression of p21, encoded by p53 target gene
CDKN1A, to mediate cell cycle G1 phase arrest. The ability of Nut-
lin3 to suppress tumour growth has been demonstrated in various
preclinical models and Nutlin3 is undergoing clinical trial evalua-
tion [40]. However, despite promising effects of Nutlin3 on induc-
ing p53 expression, Nutlin3 alone only caused modest reactivation
of p53-mediated cell death in melanoma [41,42]. Nutlin3 induced
p53 failed to induce caspase 3 and caspase 7 activity and to trigger
p53 mediated apoptosis in melanoma cell lines [42]. These obser-
vations suggest that wild type p53 is negatively regulated by other
inhibitors besides MDM2 in melanoma cells.
Recently, Gembarska et al. demonstrated that MDM4 protein
level is upregulated in around 60% of melanomas even though its
copy number is ampliﬁed in less than 7% of melanoma (Fig. 1).
SAH-p53-8, a MDM4 speciﬁc inhibitor, restored p53 function and
increased the sensitivity of melanoma to the BRAFV600E inhibitor
vemurafenib [32]. As MDM4 is poorly targeted by Nutlin3, there-
fore it may remain active upon Nutlin3 treatment. This provided
an explanation to why Nutlin3 alone is inefﬁcient in targeting mel-
anoma cells. However, a large number of melanomas do not
express high levels of MDM2 or MDM4, implying other cellular fac-
tors may also regulate p53 activity in melanoma.
4. Restoring p53 function by preventing iASPP and MDM2 from
inhibiting p53
Apoptotic function of p53, which is an irreversible process, is
tightly linked to its tumour suppression function on which the efﬁ-
cacy of many cancer therapies depends. As a therapeutic strategy,
selective reactivation of p53’s apoptotic function is an attractive
proposition. The evolutionarily conserved ASPP family of proteins
was identiﬁed as regulators of p53 induced apoptosis. The ASPP
family consists of three members, ASPP1, ASPP2 and iASPP. All
ASPP family members interact with the DBD of p53. However,
ASPP1 and ASPP2 activate whereas iASPP inhibits the apoptotic
function of p53 and its family members p63 and p73 [15,43]. All
three ASPP members have been implicated in human cancer.
Firstly, ASPP deregulation has been widely observed in various can-
cer types in past decade [14,43–47]. ASPP deregulation can be
achieved via various mechanisms. ASPP1 and ASPP2 are transcrip-
tional targets of E2F1, a key transcription factor that promotes cell
cycle G1 to S phase transition. In many cancers, ASPP1 and ASPP2
have been found to be down-regulated by promoter methylation
[48,49]. For example, reduced ASPP1 expression by promoter
methylation is associated with high relapse rate and mortality in
acute lymphoblastic leukaemia [48]. Down-regulation of ASPP2
in diffuse large B-cell and follicular centre lymphoma is also asso-
ciated with poor prognosis [47]. Secondly, ASPP deregulation also
associates with cellular sensitivity and resistance of cancer cells
to various treatments. A correlation between ASPP2 mRNA levels
and cellular sensitivity to ultraviolet and X-ray radiation in various
cancer cell lines has been described [50]. Overexpression of iASPPwas shown to induce cellular resistance to apoptosis induced by
chemotherapeutic drugs including cisplatin and paclitaxel
[43,51]. In addition, the ASPP deregulation primarily occurs in wild
type p53 expressing cells [14,43]. Interestingly, iASPP overexpres-
sion frequently occurs in cancers expressing a unique p53 poly-
morphism, p53Pro72 [52,53].
In addition to expression level, post-translational modiﬁcations
can also contribute to deregulation of ASPP activity. Lu et al.
recently reported that iASPP activity is regulated by phosphoryla-
tion [46]. Overexpressed cyclin B1/CDK1 in melanoma cells phos-
phorylates iASPP at Ser84 and Ser113, leading to the inhibition of
iASPP self-dimerization via its N and C-terminus and promoting
iASPP monomer nuclear entry. Interestingly iASPP does not contain
an identiﬁable nuclear localization signal (NLS). However, it’s
ankyrin repeats containing C-terminus possess nuclear localization
capability [54]. Mechanistically two adjacent 13th hydrophobic
residues in ankyrin repeats containing proteins form a code for
RanGDP binding. The ankyrin repeats containing proteins enter
the nucleus via RanGDP/NTF2 pathway independent of importin.
This novel nuclear import pathway is named the RaDAR
(RanGDP/Ankyrin Repeat) pathway. iASPP uses this RaDAR path-
way to enter the nucleus [55]. Compared to unphosphorylated
cytoplasmic iASPP, phosphorylated nuclear iASPP binds p53 better
and is more potent in inhibiting p53’s apoptotic function [46].
Phosphorylated nuclear iASPP, rather than cytoplasmic iASPP,
occurs in 91% of wild type p53 expressing melanoma cell lines
[46]. High levels of phosphorylated nuclear iASPP are associated
with poor survival in melanoma patients. To inhibit phosphory-
lated nuclear iASPP, a panel of G2/M kinase inhibitors was
screened and a potent cyclinB/CDK1 kinase inhibitor JNJ-7706621
was identiﬁed as the most efﬁcient inhibitor of iASPP phosphoryla-
tion at Ser84 and Ser113. Treatment with JNJ-7706621 speciﬁcally
induces p53-dependent apoptosis in wild type p53 expressing mel-
anoma cells but not in mutant p53 containing melanoma cells.
Interestingly, phosphorylated nuclear iASPP tightly correlates with
MDM2 over-expression in wild type p53 containing melanoma
cells [46], highlighting the need to co-target MDM2 and iASPP to
reactivate p53. Co-inhibition of phosphorylated nuclear iASPP
and MDM2 by JNJ-7706621 and Nutlin3 synergistically induced
apoptosis in wild type p53 expressing melanoma cells. Further-
more, they also exhibit a synthetic suppression of cell growth
in vitro and in two xenograft models. As p14ARF modulates the
p53 pathway via MDM2, a MDM2 inhibitor could also kill mela-
noma cells harbouring deleted CDKN2A. This ﬁnding provided a
proof of principle strategy to synergistically restore the tumour
suppressive function of p53 by preventing the inhibitory properties
of iASPP and MDM2 (Fig. 2, left panel).
5. Preventing other mechanisms from inactivating p53
Apart fromMDM2, MDM4, p14ARF and ASPPs, numerous p53 co-
factors (directly binding p53) and regulators (modulating p53
activity) have been reported to be deregulated in melanoma, sug-
gesting roles in inactivating melanoma p53. These include PIASy
[56], Tip60 [56,57], Y box-binding protein 1 [58,59], p63 [60],
and p73 [61]. Both p63 and p73 are rarely mutated in human can-
cer. In melanoma, both isoforms of p63 (TAp63 and DeltaNp63)
negatively regulate apoptosis through ameliorating expression of
Bcl-2 through translocation to the mitochondria and preventing
nuclear p53 stabilization in response to genotoxic stress [60]. In
case of p73, DeltaNp73 is considered as an oncoprotein since the
expression of DeltaNp73 is linked to progression and metastasis
in melanoma [61,62]. In contrast, TAp73 plays a role of tumour
suppressive role in melanoma. In wild type p53-expressing mela-
noma cells, camptothecin, a cytotoxic quinoline alkaloid which
Fig. 2. Reactivating p53 by co-targeting MDM2 and iASPP in melanoma. Left panel shows p53 is co-inhibited by phosphorylated iASPP, p14 (p14ARF, encoded by CDKN2A),
MDM2, and MDM4. Right panel shows inhibitors of cyclin B1/CDK1 (JNJ-7706621), MDM2 (Nutlin3) and BRAFV600E (vemurafenib) to achieve parallel targeting strategy for
melanoma therapy.
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p73-dependent apoptosis whereas in mutant p53-expressing
melanoma cells, p73 and caspase-2 are predominantly involved
in inducing apoptosis [63]. Recently, a study conﬁrmed the
involvement of TAp73 in inducing apoptosis in melanoma [64]. It
was found that both p53 and TAp73 can be upregulated upon
methotrexate (MTX/TMECG) treatment and consequently MTX
induced TAp73 mediated apoptosis and this property of TAp73 is
independent of p53 as it can be detected even in mutant
p53-expressing melanoma cells. Notably, ASPP is also able to bind
and regulate the p53 family members, p63 and p73 [15,65,66].
Thus, phosphorylated nuclear iASPP may also inhibit p63 and
p73 and decide melanoma cell fate.
6. Reactivating p53 as a parallel strategy in future cancer
therapy
Inactivation of the tumour suppressor p53 pathway is a com-
mon event in human cancer. p53 mutation occurs in around 50%
of human tumours, but of the remaining 50% that express structur-
ally wild type p53, many show impaired p53 function. The tumour
suppressive function of p53 in human melanoma cells is notori-
ously unresponsive. The ability to restore the apoptotic function
of p53 in melanoma cells in preclinical studies suggests that resto-
ration of p53 can serve as a parallel strategy in the treatment of
melanoma. Restoring wild type p53 function and inhibiting
BRAFV600E represents a new means of enhanced cell killing in
human melanoma and this was supported by recent studies
(Fig. 2) [32,42,46]. In agreement with this, a combined treatment
with inhibitors of BRAFV600E (vemurafenib), iASPP (JNJ-
7706621) and MDM2 (Nutlin3) suppressed the growth of wild type
p53 and BRAFV600E expressing melanoma cell lines in vitro and
xenograft tumours in vivo by at least 80% (Fig. 2, right panel). In
contrast, single-agent treatment with vemurafenib, JNJ-7706621
and Nutlin3 resulting in growth inhibition of 40%, 20% and 10%,
respectively [46]. An optimized derivative of JNJ-7706621 together
with a more potent Nutlin3 analog such as RG7112 may enhance
the apoptotic function of p53 [67]. This initial study provided a
proof of principle that the tumour suppressive function of p53
can be reactivated effectively by inhibiting both MDM2 and
phosphorylated nuclear iASPP.
With recent understanding on the complexity of p53 inactiva-
tion and the preclinical successes in p53 reactivation in melanoma,
p53-based therapy may become feasible in treating melanoma
patients by restoring p53 function. Targeting iASPP in melanoma
therapy represents a promising opportunity, although its
regulation of other binding partners such as p63 and p73 in mela-
noma requires further investigation. Given these efforts, we would
anticipate that modulating iASPP function may prove to be aneffective strategy to restore p53 function in tumours such as mel-
anoma that express structurally wild type p53. Restoration of the
tumour suppressive function of p53 presents an opportunity for
a parallel therapeutic strategy with BRAF600E inhibition to achieve
maximal efﬁcacy to kill melanoma cells. Strategies that target both
p53-dependent and -independent pathways are likely to achieve
synergistic killing in the 50% of cancers that express wild type p53.
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